PEDRO PIEDRA to Vaccines, Attenuated
This is a "connection" page, showing publications PEDRO PIEDRA has written about Vaccines, Attenuated.
Connection Strength
0.923
-
Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007 Sep; 120(3):e553-64.
Score: 0.271
-
Live Attenuated Influenza Vaccine: Will the Phoenix Rise Again? Pediatrics. 2019 02; 143(2).
Score: 0.150
-
A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation. Nat Commun. 2016 12 21; 7:13916.
Score: 0.130
-
Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis. 2010 Dec 01; 202(11):1626-33.
Score: 0.085
-
Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine. 2007 Nov 19; 25(47):8010-20.
Score: 0.068
-
Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics. 2002 Oct; 110(4):662-72.
Score: 0.048
-
Safety of the trivalent, cold-adapted influenza vaccine (CAIV-T) in children. Semin Pediatr Infect Dis. 2002 Apr; 13(2):90-6.
Score: 0.047
-
A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats. J Virol. 2016 08 15; 90(16):7508-7518.
Score: 0.032
-
Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children. Vaccine. 1993; 11(7):718-24.
Score: 0.025
-
Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J. 2008 May; 27(5):444-52.
Score: 0.018
-
Safety of cold-adapted live influenza vaccine. Pediatr Infect Dis J. 2004 Jun; 23(6):593-4; author reply 594.
Score: 0.014
-
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis. 2000 Mar; 181(3):1133-7.
Score: 0.010
-
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000 Feb; 136(2):168-75.
Score: 0.010
-
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998 May 14; 338(20):1405-12.
Score: 0.009
-
Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group. J Infect Dis. 1996 Jun; 173(6):1313-9.
Score: 0.008